# To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma

> **NCT06742138** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 284 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** QL2109
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone
- **DRUG:** DARZALEX FASPRO®

## Key facts

- **NCT ID:** NCT06742138
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 284 (ESTIMATED)
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06742138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06742138, "To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06742138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*